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Background: Betatrophin may increase islet β cell proliferation in insulin resistance and irisin may improve glucose
tolerance in mice. To examine the relationship between betatrophin and irisin, we investigated it in middle-aged
Chinese subjects with normal glucose tolerance (NGT) and type 2 diabetes mellitus (T2DM).
Methods: A total of 460 permanent residents of Fengxian District, aged 40–60 years and without T2DM, were
enrolled. Anthropometric parameters, oral glucose tolerance test (OGTT) results, glycosylated haemoglobin levels,
blood lipid levels, insulin sensitivity (homeostasis model assessment of insulin resistance, HOMA-IR), β cell function
(homeostasis model assessment-β, HOMA-β), estimated glomerular filtration rate (eGFR) and body fat composition
were determined. Matched for age, gender and body mass index (BMI, 18–28 kg/m2), newly diagnosed T2DM
(n = 50, male/female = 23/27) and NGT (n = 50, male/female = 21/29) subjects were selected based on the results
of an OGTT. Serum betatrophin and irisin levels were determined by enzyme linked immune sorbent assay (ELISA).
Results: Males had higher levels of betatrophin compared with females in both the NGT and T2DM groups.
Compared with NGT subjects, the level of betatrophin in the T2DM group was higher, and males in the T2DM
group had higher betatrophin levels than males in the NGT group, but there was no significant difference in
betatrophin levels in females between the T2DM and NGT groups. Spearman’s correlation analysis revealed that
serum betatrophin levels in females with NGT were positively correlated with irisin and negatively correlated with
FINS (fasting insulin) levels ( p < 0.05), but no correlation was found between betatrophin and irisin levels in males
with NGT or in males or females with T2DM. In females with T2DM, circulating betatrophin levels were positively
correlated with weight, BMI and hip circumference (p < 0.05) but negatively correlated with FPG (fasting plasma
glucose) and HOMA-IR (p < 0.05).
Conclusions: Gender differences in the relationship between betatrophin and irisin indicate that there might be
cytokine-mediated crosstalk among the liver, adipose tissue and skeletal muscle.
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Diabetes mellitus is one of the most common chronic
diseases, and its incidence gradually increases each year.
The world prevalence of diabetes among adults was 6.4%,
affecting 285 million adults, in 2010, and it is predicted to
increase to 7.7% (i.e., 439 million adults) by 2030 [1]. The
prevalence of diabetes was estimated at 11.6% in the Chin-
ese adult population [2], and China may be home to the
world’s largest population of people living with diabetes.
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Despite extensive research, the mechanisms are not fully
understood, and pharmacological treatments targeting in-
sulin resistance and beta cell function are almost non-
existent.
Betatrophin (also known as angiopoietin-like protein 8
(ANGPTL8), hepatocellular carcinoma-associated protein-
TD26, refeeding-induced fat and liver protein (RIFL) and
lipasin) is a newly identified hormone [3-6]. It has been
demonstrated that betatrophin, mainly expressed in liver
and adipose tissue in mice, promotes pancreatic beta cell
proliferation and improves metabolic control [5,7,8]. Re-
cently, Gusarova et al. showed that Angptl8 (−/−) mices is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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atic beta cells in response to insulin resistance resulting
from either a high-fat diet or the administration of the in-
sulin receptor antagonist S961 [9]. And Yi et al. repeated
the experiment in order to find the likely cause of this devi-
ation; finally they obtained results that some mice respond
strongly to ANGPTL8/betatrophin expression but many
do not, one possible explanation is that ANGPTL8 re-
quires a binding partner that can be induced by tail vein in-
jection; another approach to investigate this issue is to find
and investigate the function of the receptor for Angptl8/
betatrophin or its protein complex [10]. In all, whether
betatrophin does control pancreatic β cell proliferation or
not needs further study.
Betatrophin is also involved in lipid metabolism; its overex-
pression increases serum triglyceride (TG) levels and inhibits
the activity of lipoprotein lipase (LPL) [4]. Additionally, Ren
G et al. observed that betatrophin knockout mice have serum
TG levels approximately one-third of those in wild-type mice
[3] and Hobbs et al. also showed that plasma TG levels were
reduced in fed Angptl8− /−mice [11]. Serum betatrophin
levels were found to be higher in subjects with T2DM in
many studies, but there have also been studies that found no
difference in betatrophin levels and even decreased levels in
obese and T2DM subjects [12-16].
Irisin, a myokine that is produced by proteolytic cleavage
of fibronectin type III domain containing protein 5
(FNDC5), is secreted by skeletal muscles and increases
with exercise [17]. Exercise activates the expression of per-
oxisome proliferator-activated receptor-γ coactivator-1α
(PGC-1α) and uncoupling protein 1 (UCP1), which stimu-
late the proton transport chains in the mitochondrial
membrane and increase ATP and energy consumption in
the form of heat. This process results in weight loss and
improved insulin sensitivity [17-19]. Serum irisin levels
were found to be reduced in long-term, new-onset and un-
defined diabetes as well as in metabolic syndrome (MetS)
and in individuals with raised-FPG [20-23].
Zhang Y and colleagues found that irisin up-regulated
PGC-1α and UCP1, likely mediated by p38 mitogen-
activated protein kinase (p38 MAPK) and the extracellular
regulated protein kinase (ERK) signalling pathway [24].
Therefore, the p38 MAPK and ERK signalling pathways
play an important role in the process of WAT “browning”
mediated by irisin. Based on previous research, Sanchis-
Gomar et al. proposed a pathway involved in the produc-
tion of insulin resistance that influences glucose and lipid
metabolism and involves betatrophin and irisin [25]. The
mechanisms underlying type 2 diabetes include insulin se-
cretion by pancreatic β-cells and insulin resistance, which
involves hepatocytes, adipocytes and myocytes. Betatrophin
is a cytokine expressed in the liver and adipose tissue that
increases islet β cell proliferation in insulin resistance
[5,7,8], whereas irisin, which promotes white adipose tissue(WAT) “browning” and improves glucose tolerance in
mice, is a myokine as well as an adipokine [17,26]. Thus,
there might be cytokine-mediated crosstalk among the
liver, adipose tissue and skeletal muscle. Hence, the current
study aims to explore the relationship between circulating
betatrophin levels and irisin and a potential gender di-
morphism with respect to betatrophin levels.
Methods
Participants
Between December 2012 and September 2013, a
community-based health survey was performed in the
Fengxian District of Shanghai, China, to determine the
prevalence of DM and prediabetes in adults aged 40 to
60 years. A total of 460 subjects (203 men and 257 women)
successively underwent a full evaluation of their glucose tol-
erance status. Of the 460 individuals, there were 60 newly
diagnosed T2DM cases, 254 subjects with NGT and 146
subjects with pre-diabetes. Matched for age, gender and
body mass index (BMI, 18–28 kg/m2), newly diagnosed
T2DM (n = 50, male/female = 23/27) and NGT (n = 50,
male/female = 21/29) subjects were selected based on the
results of an OGTT [27]. Subjects with a fasting plasma
glucose level of ≥ 7.0 mmol/L or a 2-hour plasma glucose
level of ≥ 11.1 mmol/L were diagnosed with DM. Subjects
with T2DM were not treated with anti-diabetic medica-
tions. Individuals with a history of DM, gestational diabetes,
acute or chronic inflammatory disorders, cancer, active
hepatitis/liver cirrhosis, severe cardiovascular or kidney dis-
eases or other known major diseases were excluded from
the study. This study was approved by the Medical Ethics
Committee of the Shanghai Fengxian District Central Hos-
pital, and all subjects gave written informed consent.
Measurements
Height (without shoes) and weight (without shoes and in
light clothing) were measured, and BMI (kg/m2) was calcu-
lated by dividing the subjects’ weight (kg) by their height
(m2). The subjects stood with their feet 25–30 cm apart for
even weight distribution; waist circumference was mea-
sured midway between the lower rib margin and the iliac
crest at the end of expiration, and the hip circumference
measurement was taken around the most prominent point
of the pelvis. Blood pressure was measured 3 times using a
mercury sphygmomanometer at resting state, and an aver-
age value was obtained. Skeletal muscle, body fat mass and
body fat percentage were measured with a human body
composition analyser (INBODY S10, Korea). All blood
samples were taken in the morning following an overnight
fast of at least 8 h. After clotting, blood specimens were
separated by centrifugation, and serum samples were sub-
sequently stored in aliquots without preservatives at −80°C
until analysis of betatrophin and irisin. A 75 g glucose solu-
tion was administered orally, and plasma glucose was
Xie et al. Diabetology & Metabolic Syndrome  (2015) 7:26 Page 3 of 8measured after 2 hours. In all subjects, fasting plasma glu-
cose (FPG), 2-hour plasma glucose (2 h-PG), serum total
cholesterol (TC), triglycerides (TG), low-density lipoprotein
cholesterol (LDL), high-density lipoprotein cholesterol
(HDL), free fatty acids (FFA), blood urea nitrogen (BUN),
serum creatinine (Cr), and uric acid (UA) were measured
using an automatic biochemical analyser (Beckman
DXC800, USA). Haemoglobin A1C (HbA1C) was measured
by high-pressure liquid chromatography (TOSOH HLC-
723 G7, Japan), and fasting insulin (FINS) was measured
in an electrochemiluminescence immunoassay (ADVIA
Centaur, Germany). Homeostasis model assessment of insu-
lin resistance (HOMA-IR) values were calculated as FPG
(mM)× FINS (mU)/22.5. Homeostasis model assessment-β
(HOMA-β) values were calculated as 20 × FINS (mU)/[FPG
(mM)- 3.5]. The estimated glomerular filtration rate (eGFR)
values were calculated from creatinine levels using the
CKD-EPI formula [28]. Serum irisin levels were determined
using a commercially available human ELISA kit (PHOE-
NIX PHARMACEUTICALS, INC., USA), and plasma beta-
trophin levels were determined via ELISA (Wuhan Eiaab
Science, Wuhan, China; Catalogue No. E11644h). Intra-
assay CV and inter-assay CV of betatrophin were less than
4.8% and 7.2%; while the intra-assay CV and inter-assay CV
of irisin were less than 10% and 15%, respectively.
Statistics
Statistical analysis was performed using SPSS 19.0 software.
The data are presented as the mean ± SD or median (inter-
quartile range). Continuous variables that followed normal
distributions were compared via t-test, whereas those that
did not follow a normal distribution were compared using
the Wilcoxon signed-rank test. Correlation coefficients
were analysed using Spearman’s correlation. P values < 0.05
were considered statistically significant.
Results
Characteristics of study participants
The clinical and laboratory characteristics of the study
subjects are presented in Table 1. In subjects with NGT,
compared with female subjects, the levels of betatrophin,
height, weight, BMI, waist circumference, hip circumfer-
ence, WHR, Cr, UA, TG and FPG were significantly
higher among men (p < 0.05). In men with T2DM, beta-
trophin levels were also significantly higher than in
women with T2DM; men also had greater height,
weight, BMI, waist circumference, hip circumference, Cr
and UA (p < 0.05); however, TC and HDL levels were
significantly higher (p < 0.05) in women.
Gender dimorphism regarding circulating betatrophin
and irisin concentrations in subjects with NGT and T2DM
Compared with subjects with NGT, the level of betatro-
phin in subjects with T2DM was higher (Figure 1A), andmales with T2DM had higher betatrophin levels than males
with NGT, but there was no significant difference between
females with T2DM and females with NGT (Figure 1C).
Men had higher levels of betatrophin compared with
women in both the NGT and T2DM groups (Figure 1C).
There were no significant differences in irisin levels be-
tween the NGT and T2DM groups (Figure 1B). Moreover,
no gender difference in circulating irisin levels was found
in our study (Figure 1D).
Correlation of betatrophin with clinical parameters
Correlation coefficients between betatrophin levels and the
measured clinical parameters are presented in Figures 2
and 3. Spearman’s correlation analysis revealed that serum
betatrophin levels in females with NGT were positively
correlated with irisin and negatively correlated with FINS
(p < 0.05) (Figure 2), but no correlation was found between
betatrophin and irisin in males with NGT or in males or
females with T2DM (data not shown). In females with
T2DM, circulating betatrophin levels were positively corre-
lated with weight, BMI and hip circumference but nega-
tively correlated with FPG and HOMA-IR (p < 0.05)
(Figure 3).
Discussion
Diabetes is a public health problem throughout the
world as well as in China, and it is particularly important
to explore treatments that focus on the mechanisms of
diabetes—impaired pancreatic beta cell function and in-
sulin resistance. Betatrophin and irisin are two novel
hormones that have been intensively investigated in re-
cent diabetes treatment research that potentially take
part in the mechanisms of T2DM associated with insulin
resistance and β cell function.
Betatrophin has been identified as a novel hormone
that belongs to the family of angiopoietin-like proteins
and is coded by Gm8464 (in mice) and C19orf80 (in hu-
man) [3]. It has been demonstrated that betatrophin is a
liver- and fat-derived hormone that promotes pancreatic
β cell proliferation and improves glucose tolerance [5].
Espes and colleagues measured betatrophin concentra-
tions in humans for the first time and observed that
serum betatrophin levels were approximately doubled in
patients with type 1 diabetes compared with controls
[29]. Our study demonstrated that circulating betatro-
phin levels were significantly higher in newly diagnosed
T2DM subjects than in NGT subjects; this finding was
consistent with the results of Espes’s recent research on
T2DM [14] as well as research by Fu et al. [12] and Hu
et al. [13]. However, one recent study reported that beta-
trophin concentrations did not differ between T2DM
and non-diabetic participants [15], and another reported
decreased betatrophin levels in obese and T2DM sub-
jects [16]. The paradoxical results may be related to the
Table 1 Baseline clinical characteristics of subjects with normal glucose tolerance (NGT) and type 2 diabetes mellitus
(T2DM)
Factor NGT T2DM
Male Female P Male Female P
N 21 29 23 27
Age (years) 53.00 (46.50,57.50) 55.00 (49.50,58.00) 0.903 51.82 ± 6.91 51.65 ± 4.66 0.925
Height (cm) 165.76 ± 8.29 154.81 ± 4.13 <0.001* 165.91 ± 5.21 156.06 ± 5.46 <0.001*
Weight (kg) 69.67 ± 7.36 57.36 ± 5.77 <0.001* 70.65 ± 5.88 58.37 ± 7.71 <0.001*
BMI (kg/m2) 25.33 ± 1.56 23.81 ± 2.17 0.009* 25.65 (24.92,26.18) 23.92 (22.76,25.21) 0.003*
Waist (cm) 85.95 ± 4.92 79.91 ± 9.26 0.005* 87.59 ± 4.51 82.79 ± 8.60 0.017*
Hip (cm) 92.14 ± 3.48 89.30 ± 4.40 0.019* 92.80 ± 3.51 89.77 ± 6.51 0.046*
WHR 0.9 3(0.89, 0.98) 0.90 (0.81, 0.94) 0.038* 0.94 ± 0.05 0.92 ± 0.09 0.339
SBP (mmHg) 124.00 (110.00, 134.00) 120.00 (110.00, 130.00) 1.00 130.00 (124.00, 150.00) 140.00 (120.00, 141.00) 0.755
DBP (mmHg) 80.00 (70.00, 90.00) 80.00 (73.00, 85.50) 0.688 90.00 (77.50, 100.00) 83.00 (74.50, 90.00) 0.559
Body fat (kg) 17.48 ± 3.81 19 ± 4.98 0.256 22.49 ± 4.16 20.21 ± 4.52 0.088
BFR (%) 29.05 ± 6.38 30.93 ± 6.71 0.331 32.68 ± 4.56 31.90 ± 5.11 0.596
Muscle mass (kg) 23.74 ± 4.83 23.34 ± 5.25 0.788 25.78 ± 5.49 23.61 ± 3.84 0.140
BUN (mM) 4.76 ± 0.90 5.08 ± 1.77 0.450 4.86 ± 1.00 4.72 ± 1.04 0.627
Cr (uM) 70.10 ± 9.56 54.97 ± 8.75 <0.001* 65.00 ± 11.65 50.70 ± 12.06 <0.001*
UA (uM) 336.24 ± 81.71 223.62 ± 66.61 <0.001* 329.30 ± 78.76 269.67 ± 67.13 0.006*
eGFR (rml/min/1.73 m2) 100.86 ± 11.27 102.74 ± 9.04 0.516 107.63 ± 10.29 109.81 ± 14.63 0.551
TC (mM) 5.10 ± 0.85 5.32 ± 1.27 0.484 4.90 (1.18, 3.31) 5.67 (5.45, 5.90) 0.041*
TG (mM) 1.77 ± 1.04 1.08 ± 0.52 0.009* 1.75 (1.16, 3.33) 1.22 (0.96, 1.89) 0.298
HDL (mM) 1.23 ± 0.24 1.37 ± 0.25 0.054 1.24 ± 0.22 1.48 ± 0.54 0.040*
LDL (mM) 2.94 ± 0.60 3.15 ± 0.95 0.387 2.93 ± 0.82 3.24 ± 0.97 0.233
FFA (mM) 0.38 ± 0.19 0.40 ± 0.16 0.643 0.54 ± 0.27 0.82 ± 1.04 0.234
FPG (mM) 5.40 ± 0.42 5.13 ± 0.42 0.027* 7.47(6.40,8.80) 6.80(6.15,9.43) 0.477
2 h-PG (mM) 5.85 ± 1.32 6.33 ± 3.26 0.118 14.65(12.15,17.73) 14.15(12.15,19.73) 0.586
HbA1C (%) 5.55 (5.30, 5.70) 5.40 (5.20, 5.60) 0.206 6.60 (5.80, 8.20) 6.50 (5.90, 8.38) 0.741
FINS (mU/l) 4.15 (3.21, 6.71) 5.67 (3.82, 6.72) 0.254 8.85 (6.26, 11.53) 9.07 (6.47, 12.13) 0.969
HOMA-IR 1.38 ± 0.75 1.71 ± 0.91 0.182 2.82 (2.04, 3.31) 2.77 (2.27, 5.00) 0.633
HOMA-β (%) 27.67 (19.67, 60.77) 35.70 (25.00, 54.10) 0.331 43.25 (30.03, 62.47) 53.64 (33.12, 81.99) 0.430
Betatrophin (pg/ml) 299.61(146.56,439.65) 242.07(67.68,319.41) 0.033* 498.86 ± 239.79 334.59 ± 216.42 0.014*
Irisin (ng/ml) 244.38 (214.18, 305.92) 243.57 (193.49, 347.25) 0.687 249.53 (202.21, 455.08) 241.81 (205.82, 278.94) 0.808
Data are presented as the mean ± SD or median (interquartile range). *,P<0.05.
BMI: body mass index; WHR: waist-to-hip ratio; SDP: systolic blood pressure; DBP: diastolic blood pressure; BFR: body fat rate; BUN: blood urea nitrogen; Cr: creatinine;
UA: uric acid; eGFR: estimated glomerular filtration rate; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein
cholesterol; FFA: free fatty acids; FPG: fasting plasma glucose; 2 h-PG: 2 h plasma glucose; HbA1C: hemoglobin A1C; FINS: fasting insulin HOMA-IR: homeostasis model
assessment of insulin resistance; HOMA-β: homeostasis model assessment-β.
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the previous study was higher than 30 kg/m2, and the
participants in the present study had BMIs between 18
and 28 kg/m2. Second, all patients with T2DM in Fenzl
et al.’s study received medication, and the patients with
T2DM in the present study were all newly diagnosed
and were not receiving medication. Third, a recent pub-
lication suggests that the differences in recent findings
on betatrophin should be discussed in light of differ-
ences between two commercially available ELISA kits[30], and this may help explain the paradoxical results.
Finally, we cannot exclude that increased betatrophin
levels may be transient due to functional compensation
of pancreatic β cells in early diabetes.
Our data also revealed a sexual dimorphism with respect
to betatrophin levels and demonstrated that serum betatro-
phin concentrations were significantly lower in women
than in men. Gómez-Ambrosi et al. [16] were the first to
report this dramatic gender dimorphism in betatrophin
levels; however, the results they obtained were inconsistent
Figure 1 Gender dimorphism of circulating betatrophin and irisin concentrations in NGT and T2DM. A. Comparison of serum betatrophin
concentrations between NGT and T2DM. B. Comparison of serum irisin concentrations between NGT and T2DM. C. Comparison of serum
betatrophin concentrations between males and females with NGT and T2DM. D. Comparison of serum irisin concentrations between males and
females with NGT and T2DM.
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trophin levels were found in females than in males. The
differing results may be attributed to differences in test kits
or subject characteristics. Fu et al. compared the betatro-
phin kits manufactured by Eiaab (Catalogue no. E1164H;
Wuhan, China) and Phoenix Pharmaceuticals (Catalogue
no. EK-051-55; Burlingame, CA, USA) [30]. They found
that two kits used different antibodies, which recognized
the N- and C-terminus of betatrophin, respectively. They
indicated that serum betatrophin levels were positively or
negatively correlated with BMI in studies using Eiaab or
Phoenix Pharmaceuticals’ kits. Therefore, the use of differ-
ent kits may help explain the paradoxical results with re-
spect to gender differences in the two studies.
Yi and colleagues found that overexpression of betatro-
phin in mice causes a 17-fold increase in β cell prolifera-
tion, and the specific deletion of β cells with diphtheriaFigure 2 Correlation analysis to evaluate the correlation of circulating
bivariate correlation analysis showed that FINS (r = -0.375, p <0.05) was neg
p<0.05) was positively correlated with circulating betatrophin , the figurestoxin did not up-regulate betatrophin, suggesting that beta-
trophin levels are regulated by insulin resistance but not
insulin deficiency [5]. The result that the HOMA-IR in
T2DM subjects was higher than that in NGT (data not
shown) suggests that insulin resistance in T2DM subjects
is more common than in NGT subjects. At the same time,
betatrophin levels were related to HOMA-IR in women
with T2DM, and these results were consistent with the re-
sults of previous animal studies, in which it was observed
that betatrophin could improve insulin resistance.
The characteristics of insulin resistance include senility,
obesity, higher SBP, low HDL-cholesterol levels, increased
TG concentrations and low alcohol intake [31]. Betatro-
phin levels in T2DM were associated with BMI and waist
circumstance, but there was no correlation between beta-
trophin concentrations and age, SBP, HDL-cholesterol or
TG (data not shown). In females with T2DM, circulatingbetatrophin with irisin and FINS in women with NGT. Spearman
atively correlated with circulating betatrophin and irisin (r=0.391,
were presented in A and B.
Figure 3 Correlation analysis to evaluate the correlation of circulating betatrophin with weight, BMI, hip circumference, FBG and
HOMA-IR in women with T2DM. Spearman bivariate correlation analysis showed that weight (r =0.501, p <0.01), BMI (r =0.449, p <0.05) and hip
circumference (r=0.392, p<0.05) were positively correlated with circulating betatrophin, the figures were presented in A, B and C; FBG (r=-0.441,
p<0.05) and HOMA-IR (r=-0.419,p<0.05) were negatively correlated with circulating betatrophin, the figures were presented in D and E.
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BMI and hip circumference. These findings were partly in-
consistent with the results of a previous study on T2DM.
Fenzl et al. observed that betatrophin levels were associated
with LDL-cholesterol and TC but not BMI [15]. However,
Espes et al. found that age, BMI, SBP, HDL-C and TG were
all not associated with betatrophin [14]. The differing re-
sults may be attributable to race and BMI differences.
In many studies, serum irisin levels have been found to
be reduced in T2DM subjects. Liu et al. studied 96 T2DM
and 60 non-diabetic subjects and found that circulating iri-
sin was significantly lower in subjects with long-term
T2DM compared with non-diabetic controls [20]. De-
creased circulating irisin was also found in subjects with
new-onset T2DM by Choi Y.K. [21], in raised-FPG subjects
by Yan B. et al. [22] and in undefined T2DM-status sub-
jects by Moreno-Navarrete et al. [23]. However, in our
study, there were no significant differences in irisin levels
between NGT and T2DM subjects. Moreover, no genderdifferences in circulating irisin levels were found in our
study. Gender differences in irisin levels were also not
found in middle-aged adults in a previous study [23]. How-
ever, higher irisin levels were previously reported in healthy
girls compared with boys [32] and young healthy women
compared with men [33]. In another study, obese men had
higher irisin than women [34].
Based on previous studies, Sanchis-Gomar et al. hypoth-
esized that there is a pathway in which irisin and betatro-
phin are involved in insulin resistance [25]. The authors
discovered that exercise increases ROS levels and then acti-
vates p38 MAPK, which regulates PGC-1α by inducing the
expression of FNDC5. FNDC5 cleaves and secretes irisin,
which acts on WAT to stimulate UCP1 expression. Fur-
thermore, this activity promotes the expression of betatro-
phin and β cell proliferation and reduces insulin resistance.
Our study demonstrated that betatrophin levels were
positively associated with irisin in women with NGT, and
this was consistent with the hypothesis proposed by
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ing this hypothesis, our results suggested the increased
likelihood of a p38-PGC-1α–irisin–betatrophin axis in
humans. However, our study found no correlation between
betatrophin and irisin in women with newly diagnosed
T2DM, which might be due to the following reasons: exer-
cise involved in irisin expression and secretion was not
evaluated in this study, and diabetes mellitus is a group of
metabolic diseases influenced by many factors (such as
obesity, blood lipids, insulin, dietary and so on), and we
only excluded the confounding factor of obesity in our
study.
There were several limitations regarding the design of
this study. A major limitation of this study is the small
number of patients who were available for analysis. A
secondary limitation was its retrospective design. The
final limitation was that we were not able, because of
funding constraints, to obtain data after OGTT.
Conclusions
Our study demonstrated that serum betatrophin levels in
NGT subjects were lower than in newly diagnosed T2DM
subjects and that males had higher levels of betatrophin
than females in both the NGT and T2DM groups. More-
over, betatrophin levels were associated with serum irisin
and FINS in women with NGT, whereas there was no cor-
relation between betatrophin and irisin in subjects with
newly diagnosed T2DM; circulating betatrophin was posi-
tively correlated with weight, BMI and hip circumference
but negatively correlated with FPG and HOMA-IR. The re-
sults indicate that betatrophin and irisin may play a role in
the mechanisms underlying T2DM associated with insulin
resistance and β cell function, and cytokine-mediated
crosstalk may occur among the liver, adipose tissue and
skeletal muscle.
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glucose; TC: Total cholesterol; TG: Triglyceride; LDL: Low-density lipoprotein
cholesterol; HDL: High-density lipoprotein cholesterol; FFA: Free fatty acids;
BUN: Blood urea nitrogen; Cr: Creatinine; UA: Uric acid; eGFR: Estimated
glomerular filtration rate; HbA1C: Haemoglobin A1C; FINS: Fasting insulin;
HOMA-IR: Homeostasis model assessment of insulin resistance;
HOMA-β: Homeostasis model assessment-β; WHR: Waist-hip ratio; SDP: Systolic
blood pressure; DBP: Diastolic blood pressure; BFR: Body fat rate.
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